





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

(11) International Publication Number:

WO 00/58341

C07K 1/00, 14/00, A61K 38/00

**A1** 

(43) International Publication Date:

5 October 2000 (05.10.00)

(21) International Application Number:

PCT/US00/08519

(22) International Filing Date:

30 March 2000 (30.03.00)

(30) Priority Data:

60/127,239

31 March 1999 (31.03.99) US BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG,

MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

VERSITY [US/US]; 155 Whitney Avenue, New Haven, CT 06520-8336 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CAPPELLO, Michael [US/US]; 99 Marvel Road, New Haven, CT 06515 (US). CHADDERDON, Robert, C. [US/US]; 42 Wolf Road, Unit 113, Lebanon, NH 03766 (US). DEL VALLE, Antonio [US/US]; 140 Mill Street, Apt. 20-157, East Haven, CT 06512 (US). HARRISON, Lisa, M. [US/US]; 21 Marldon Road, RR # 3, Brookville, CT 06804 (US).

(71) Applicant (for all designated States except US): YALE UNI-

(74) Agent: KRINSKY, Mary, M.; 79 Trumbull Street, New Haven, CT 06511-3708 (US).

Published

With international search report.

(54) Title: HOOKWORM PLATELET INHIBITOR

(57) Abstract

An inhibitor of platelet aggregation and adhesion is purified and characterized from soluble protein extracts of adult Ancylostoma caninum hookworms, and then cloned and sequenced. The inhibitor blocks platelet aggregation in response to a variety of agonists, interfering with the binding of at least one cell surface integrin with its respective ligand. Embodiments include inhibition of the binding of fibrinogen to cell surface integrin GPIIb/IIIa ( $\alpha_{\text{IIb}}\beta_3$ ) and inhibition of the binding of collagen to cell surface integrin GPIa/IIa ( $\alpha_2\beta_1$ ). Medical and veterinary pharmaceutical and immunological compositions containing the platelet inhibitor, and methods of using it, are described.



